New drug combo shows promise in aggressive lymphoma trial
NCT ID NCT04231448
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This phase 3 trial tested adding the drug tucidinostat to standard chemotherapy (R-CHOP) in 423 adults with a fast-growing type of lymphoma called double-expressor DLBCL. The goal was to see if the combination could delay the cancer from coming back or getting worse. Participants took either tucidinostat or a placebo pill along with their chemo, and researchers tracked how long they stayed cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
-
Shanghai JiaoTong University School of Medicine，Ruijin Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.